Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31150564 | 1.00 | HCAR2 (0.52) | HCAR2SMYD3S1PR4S1PR3PTGS1 | |
| SCHEMBL15731685 | 0.78 | HCAR2 (0.46) | HCAR2SMYD3S1PR4S1PR3MKNK1 | |
| SCHEMBL4217222 | 0.78 | POLB (0.53) | HCAR2SMYD3EGFR | |
| SCHEMBL640931 | 0.76 | HCAR2 (0.52) | HCAR2SMYD3PTGS2EGFR | |
| SCHEMBL25186926 | 0.76 | HCAR2 (0.52) | HCAR2PTGS1PTGS2EGFR | |
| SCHEMBL30936046 | 0.75 | HCAR2 (0.55) | HCAR2SMYD3MKNK1MKNK2 | |
| SCHEMBL2225246 | 0.74 | HCAR2 (0.55) | HCAR2PTGS1PTGS2MKNK1MKNK2 | |
| Hydrochloric Acid SCHEMBL14486940 | 0.73 | HCAR2 (0.53) | HCAR2SMYD3MKNK1MKNK2 | |
| SCHEMBL2534773 | 0.72 | HDAC4 (0.40) | — | |
| SCHEMBL1421518 | 0.72 | HCAR2 (0.42) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336609-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| EP-4433473-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2024-09-25 | — | — | EP | disclosed |
| WO-2023091606-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023091606-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | EDGEWISE THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336609-A1 | PYRIDAZINONE COMPOUNDS AND USES THEREOF | IL6, IL1B, IL1A | HCAR2 2141/4885SMYD3 4671/4885S1PR4 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.